LCTX icon

Lineage Cell Therapeutics

106 hedge funds and large institutions have $130M invested in Lineage Cell Therapeutics in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.

Holders
106
Holders Change
-1
Holders Change %
-0.93%
% of All Funds
2.43%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
10
Increased
30
Reduced
23
Closed
11
Calls
$215K
Puts
$78K
Net Calls
+$137K
Net Calls Change
+$192K
Name Market Value Shares Shares
Change
Shares
Change %
VIA
101
Vantage Investment Advisors
Pennsylvania
$1K 500
PA
102
Parallel Advisors
California
$1K 274
Renaissance Technologies
103
Renaissance Technologies
New York
-145,600 Closed
Jacobs Levy Equity Management
104
Jacobs Levy Equity Management
New Jersey
-103,838 Closed
RA
105
Raffles Associates
New York
-45,000 Closed
GPCM
106
Granite Point Capital Management
Massachusetts
-37,791 Closed
Ameriprise
107
Ameriprise
Minnesota
-37,597 Closed
Russell Investments Group
108
Russell Investments Group
United Kingdom
-31,302 Closed
Susquehanna International Group
109
Susquehanna International Group
Pennsylvania
-30,350 Closed
CS
110
Credit Suisse
Switzerland
-29,984 Closed
TRCT
111
Tower Research Capital (TRC)
New York
$0 30 -19,190 -100%
ARTA
112
A.R.T. Advisors
New York
-11,631 Closed
PIA
113
Piedmont Investment Advisors
North Carolina
-1,555 Closed
PCM
114
Poehling Capital Management
Wisconsin
-1,000 Closed
OIA
115
OneDigital Investment Advisors
Kansas
$0 100
PNC Financial Services Group
116
PNC Financial Services Group
Pennsylvania
$0 300
Group One Trading
117
Group One Trading
Illinois
HNB
118
Huntington National Bank
Ohio
$0 200
CFGS
119
Concourse Financial Group Securities
Alabama
FRA
120
Front Row Advisors
California